8-K: Cannabis Bioscience International Holdings Enters Research Agreement and Appoints New Director

Cannabis Bioscience International Holdings has entered into a master research agreement with Alpha Research Institute and appointed John Jones as a director and treasurer, while also adjusting interest rates on a promissory note.

Summary

• Cannabis Bioscience International Holdings has entered into a Master Research Agreement with Alpha Research Institute, a wholly-owned subsidiary, for clinical trials to collect medical data for product development.
• The agreement, effective May 1, 2024, involves Alpha conducting trials and providing data to Vita Biotech Research LLC, with payments of $50,000 per month.
• The agreement has an initial term of four months, automatically renewing unless terminated with 30 days' notice.
• John Jones has been appointed as a director and treasurer of the company, effective August 20, 2024.
• Jones will receive 125,000,000 shares of common stock annually for four years, starting May 31, 2025, if he remains treasurer.
• The company has also reduced the interest rate on a promissory note held by Jones and Kamienski to 2.5% monthly and reduced monthly payments to $5,000.
• Jones has agreed to make efforts to raise $250,000 in equity for the company within a year, in exchange for 1,000 shares of Series B Preferred Stock.
• The company has also issued 125,000,000 shares of common stock to Jose Torres Torres for his services as secretary for the year ended May 31, 2024, and similar amounts for the following three years if he remains in the role.
• The company's articles of incorporation were amended on August 12, 2024, to increase the number of shares designated as Series B Preferred Stock to 2,000.
• The company has adopted a code of conduct, an insider trading policy, and a clawback policy on August 11, 2024.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The research agreement and new director are positive, but the debt and share dilution are concerning. The sentiment is cautiously optimistic.

Positives

• The Master Research Agreement provides a revenue stream of $50,000 per month for Alpha Research Institute.
• The appointment of John Jones as director and treasurer brings financial expertise and potential capital raising capabilities.
• The reduction in interest rates and monthly payments on the promissory note improves the company's financial position.
• The issuance of shares to key personnel incentivizes their continued service.
• The adoption of corporate governance policies enhances transparency and accountability.

Negatives

• The company is reliant on Jones to raise $250,000 in equity, which is not guaranteed.
• The company is issuing a large number of shares to officers, which could dilute existing shareholders.
• The company has a history of promissory notes and debt, which could indicate financial instability.
• The company has had a recent director death, which may indicate internal issues.

Risks

• The success of the research agreement depends on the ability of Alpha Research Institute to conduct successful clinical trials.
• The company's ability to raise capital is dependent on Jones' efforts, which may not be successful.
• The company's financial stability is still uncertain, given the reliance on promissory notes and debt.
• The company's share price could be negatively impacted by the large number of shares issued to officers.
• The company's reliance on a small number of key personnel could pose a risk if they leave.

Future Outlook

The company anticipates continued revenue from the research agreement and potential capital infusion from Jones' efforts. The company will continue to issue shares to key personnel over the next three years.

Management Comments

• The company seeks to develop and maintain relationships of trust between the Company and its personnel, on the one hand, and, on the other hand, government officials, regulatory authorities, health care professionals, patients, suppliers, customers and investors is essential and expected.
• Obeying the law in letter and in spirit is the foundation of the Company's ethical standards.

Industry Context

The agreement reflects a growing trend in the biotechnology industry where companies outsource research and development to specialized institutions. The appointment of a financial expert as a director and treasurer is common for companies seeking to raise capital.

Comparison to Industry Standards

• The monthly payment of $50,000 for clinical trials is within the range of similar agreements in the biotech industry, but the specific terms depend on the scope and complexity of the trials.
• The interest rate reduction on the promissory note is a positive step for the company, but the overall debt level remains a concern.
• The issuance of shares to officers is a common practice, but the large number of shares issued could be dilutive to existing shareholders.
• The adoption of corporate governance policies is in line with industry best practices and regulatory requirements.
• Comparable companies in the biotech sector often have similar research agreements with universities or research institutions, such as those between pharmaceutical companies and contract research organizations (CROs).
• The appointment of a treasurer with a focus on capital raising is similar to the strategies of many early-stage biotech companies that need to secure funding for their operations and research.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into a Master Research Agreement with Alpha Research Institute, a wholly-owned subsidiary.
• The company has a promissory note with John Jones and Barbara Kamienski, who are also involved in the company's operations.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the new corporate governance policies and the potential for growth.
• Customers may benefit from the development of new products through the research agreement.
• Creditors may be impacted by the company's debt restructuring and potential capital raise.
• Suppliers may be impacted by the company's new vendor policies.

Next Steps

• Alpha Research Institute will begin conducting clinical trials under the Master Research Agreement.
• John Jones will begin his duties as director and treasurer and attempt to raise $250,000 in equity.
• The company will continue to issue shares to key personnel over the next three years.
• The company will monitor compliance with the newly adopted corporate governance policies.

Key Dates

Keywords

clinical trials, research agreement, master agreement, biospecimens, data collection, director appointment, treasurer, promissory note, equity raise, share issuance, corporate governance, insider trading, clawback policy